Roth Capital Comments on Regeneron (REGN) Following Q2 Results; Affirms 'Buy' Rating
Roth Capital affirms Regeneron Pharmaceuticals (Nasdaq: REGN) at Buy with a target price of $399 following Q2 results.Analyst Joseph Pantginis ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)